8Q2T
Crystal structure of YTHDC1 in complex with Compound 5 (ZA_236)
8Q2T の概要
エントリーDOI | 10.2210/pdb8q2t/pdb |
分子名称 | YTH domain-containing protein 1, 2-chloranyl-~{N}-methyl-9-(phenylmethyl)purin-6-amine, SULFATE ION, ... (4 entities in total) |
機能のキーワード | ythdc1, inhibitor, complex, reader, rna binding protein |
由来する生物種 | Homo sapiens (human) |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 38771.47 |
構造登録者 | |
主引用文献 | Zalesak, F.,Nai, F.,Herok, M.,Bochenkova, E.,Bedi, R.K.,Li, Y.,Errani, F.,Caflisch, A. Structure-Based Design of a Potent and Selective YTHDC1 Ligand. J.Med.Chem., 67:9516-9535, 2024 Cited by PubMed Abstract: N-Adenosine methylation (mA) is a prevalent post-transcriptional modification of mRNA, with YTHDC1 being the reader protein responsible for recognizing this modification in the cell nucleus. Here, we present a protein structure-based medicinal chemistry campaign that resulted in the YTHDC1 inhibitor , which shows an equilibrium dissociation constant () of 49 nM. The crystal structure of the complex (1.6 Å resolution) validated the design. Compound is selective against the cytoplasmic mA-RNA readers YTHDF1-3 and YTHDC2 and shows antiproliferative activity against the acute myeloid leukemia (AML) cell lines THP-1, MOLM-13, and NOMO-1. For the series of compounds that culminated into ligand , the good correlation between the affinity in the biochemical assay and antiproliferative activity in the THP-1 cell line provides evidence of YTHDC1 target engagement in the cell. The binding to YTHDC1 in the cell is further supported by the cellular thermal shift assay. Thus, ligand is a tool compound for studying the role of YTHDC1 in AML. PubMed: 38787793DOI: 10.1021/acs.jmedchem.4c00599 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.41 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード